123 related articles for article (PubMed ID: 8062193)
1. Acute renal toxicity associated with suramin in the treatment of prostate cancer.
Figg WD; Cooper MR; Thibault A; Headlee D; Humphrey J; Bergan RC; Reed E; Sartor O
Cancer; 1994 Sep; 74(5):1612-4. PubMed ID: 8062193
[TBL] [Abstract][Full Text] [Related]
2. Acute renal failure in a patient receiving treatment with suramin.
Smith A; Harbour D; Liebmann J
Am J Clin Oncol; 1997 Aug; 20(4):433-4. PubMed ID: 9256906
[TBL] [Abstract][Full Text] [Related]
3. A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response.
Bowden CJ; Figg WD; Dawson NA; Sartor O; Bitton RJ; Weinberger MS; Headlee D; Reed E; Myers CE; Cooper MR
Cancer Chemother Pharmacol; 1996; 39(1-2):1-8. PubMed ID: 8995493
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer.
Dawson NA; Figg WD; Cooper MR; Sartor O; Bergan RC; Senderowicz AM; Steinberg SM; Tompkins A; Weinberger B; Sausville EA; Reed E; Myers CE
J Clin Oncol; 1997 Apr; 15(4):1470-7. PubMed ID: 9193342
[TBL] [Abstract][Full Text] [Related]
5. Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study.
Hussain M; Fisher EI; Petrylak DP; O'Connor J; Wood DP; Small EJ; Eisenberger MA; Crawford ED
J Clin Oncol; 2000 Mar; 18(5):1043-9. PubMed ID: 10694555
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
Dawson N; Figg WD; Brawley OW; Bergan R; Cooper MR; Senderowicz A; Headlee D; Steinberg SM; Sutherland M; Patronas N; Sausville E; Linehan WM; Reed E; Sartor O
Clin Cancer Res; 1998 Jan; 4(1):37-44. PubMed ID: 9516950
[TBL] [Abstract][Full Text] [Related]
7. Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma.
Falcone A; Antonuzzo A; Danesi R; Allegrini G; Monica L; Pfanner E; Masi G; Ricci S; Del Tacca M; Conte P
Cancer; 1999 Aug; 86(3):470-6. PubMed ID: 10430255
[TBL] [Abstract][Full Text] [Related]
8. Anaphylactoid reaction with suramin.
Thibault A; Figg WD; Cooper MR; Prindiville SA; Sartor AO; Headlee DJ; Myers CE
Pharmacotherapy; 1993; 13(6):656-7. PubMed ID: 8302692
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables.
Dawson NA; Cooper MR; Figg WD; Headlee DJ; Thibault A; Bergan RC; Steinberg SM; Sausville EA; Myers CE; Sartor O
Cancer; 1995 Aug; 76(3):453-62. PubMed ID: 8625127
[TBL] [Abstract][Full Text] [Related]
10. Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer.
Kelly WK; Scher HI; Mazumdar M; Pfister D; Curley T; Leibertz C; Cohen L; Vlamis V; Dnistrian A; Schwartz M
J Clin Oncol; 1995 Sep; 13(9):2214-22. PubMed ID: 7666079
[TBL] [Abstract][Full Text] [Related]
11. Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma a multicenter Phase II study.
Calvo E; Cortés J; Rodríguez J; Sureda M; Beltrán C; Rebollo J; Martínez-Monge R; Berián JM; de Irala J; Brugarolas A
Cancer; 2001 Nov; 92(9):2435-43. PubMed ID: 11745301
[TBL] [Abstract][Full Text] [Related]
12. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer.
Sartor O; Cooper M; Weinberger M; Headlee D; Thibault A; Tompkins A; Steinberg S; Figg WD; Linehan WM; Myers CE
J Natl Cancer Inst; 1994 Feb; 86(3):222-7. PubMed ID: 7506794
[TBL] [Abstract][Full Text] [Related]
13. Suramin-induced skin reactions.
O'Donnell BP; Dawson NA; Weiss RB; Myers CE; James WD
Arch Dermatol; 1992 Jan; 128(1):75-9. PubMed ID: 1531404
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer.
Tu SM; Pagliaro LC; Banks ME; Amato RJ; Millikan RE; Bugazia NA; Madden T; Newman RA; Logothetis CJ
Clin Cancer Res; 1998 May; 4(5):1193-201. PubMed ID: 9607577
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer.
Kelly WK; Curley T; Leibretz C; Dnistrian A; Schwartz M; Scher HI
J Clin Oncol; 1995 Sep; 13(9):2208-13. PubMed ID: 7545218
[TBL] [Abstract][Full Text] [Related]
16. [Recent multicenter study protocols in the USA for patients with metastatic prostatic carcinoma].
DeAntoni E; Crawford ED
Urologe A; 1995 Sep; 34(5):382-8. PubMed ID: 7483154
[TBL] [Abstract][Full Text] [Related]
17. Suramin and prostate cancer: the role of hydrocortisone.
Harland SJ; Duchesne GM
Eur J Cancer; 1992; 28A(6-7):1295. PubMed ID: 1627399
[No Abstract] [Full Text] [Related]
18. [Treatment of metastatic adrenal carcinoma with suramin].
Allolio B; Jaursch-Hancke C; Reincke M; Arlt W; Metzler U; Winkelmann W
Dtsch Med Wochenschr; 1989 Mar; 114(10):381-4. PubMed ID: 2924693
[TBL] [Abstract][Full Text] [Related]
19. Suramin in adrenocortical cancer: limited efficacy and serious toxicity.
Arlt W; Reincke M; Siekmann L; Winkelmann W; Allolio B
Clin Endocrinol (Oxf); 1994 Sep; 41(3):299-307. PubMed ID: 7955436
[TBL] [Abstract][Full Text] [Related]
20. Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy.
Rosen PJ; Mendoza EF; Landaw EM; Mondino B; Graves MC; McBride JH; Turcillo P; deKernion J; Belldegrun A
J Clin Oncol; 1996 May; 14(5):1626-36. PubMed ID: 8622081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
